PubMed
Afamelanotide for erythropoietic protoporphyria
Langendonk JG, Balwani M, Anderson KE, et al. N Engl J Med. 2015
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 43% · Mixed 42% · Unfavorable overall 15%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.1–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 53% said they felt similar to their last entry, 29% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 15 days · Based on 255 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 64% · Mixed 18% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 18 days · Based on 319 repeat reporters
Published sources linked on the Melanotan I and Melanotan II wiki pages.
PubMed
Langendonk JG, Balwani M, Anderson KE, et al. N Engl J Med. 2015
PubMed
2024
PubMed
Sweeney P, Gimenez LE, Hernandez CC, et al. Nature reviews. Endocrinology. 2023
PubMed
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
PubMed
Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021
PubMed
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012